Overview

Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis

Status:
Completed

Trial end date:
2015-04-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to investigate the efficacy and safety of 12 weeks of simeprevir (150 mg qd) in combination with sofosbuvir (400 mg qd) in chronic hepatitis C virus (HCV) genotype 1 infected men and women with cirrhosis who are HCV treatment-naïve or treatment-experienced.

Phase:

Phase 3

Details

Lead Sponsor:

Janssen Infectious Diseases BVBA

Treatments:

Simeprevir
Sofosbuvir